Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

NCT07618325 is registered in ClinicalTrials.gov with MAXVAX Biotechnology Limited Liability Company as lead sponsor.

NCT NCT07618325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07618325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 2, 2026
Completion date
August 31, 2028
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)